Latest Investor Confidence News

Mayfield Childcare reported a 14.9% revenue increase driven by acquisitions but suffered a steep $21.9 million net loss, with auditors flagging related party disclosure issues.

Astron Limited has finalized its move from Hong Kong to Australia, issuing new securities on a two-for-one basis and preparing for ASX trading starting September 1, 2025.

Perpetual Resources has launched a prospectus to enable trading of new options issued alongside a recent $1.6 million placement, aiming to unlock liquidity while outlining key risks for investors.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Spenda Limited reported a 106% surge in revenue to $11.1 million for FY25, driven by acquisitions and expanded services, yet posted a substantial $24.3 million net loss largely due to goodwill impairment. The company’s strategic moves and funding needs highlight a pivotal phase ahead.

Duxton Water Limited has declared its 17th consecutive dividend increase at 3.72 cents per share, fully franked, while removing the discount on its Dividend Reinvestment Plan following a major debt repayment.

Prestal Holdings reported a sharp 25% revenue decline and a staggering 133% increase in net loss for FY2025, yet still declared a special dividend and capital return.

Enterprise Metals Limited has addressed recent sharp price and volume movements in its shares, attributing the activity to upcoming drilling programs and positive market sentiment in rare earth elements and critical minerals.

Aspermont Limited invites existing shareholders to participate in a $1.25 million Share Purchase Plan at a premium price, supporting its pivot to data-driven intelligence services and a strategic Rio Tinto partnership.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

Prescient Therapeutics has completed a $3 million share placement, bolstering its clinical development programs for innovative cancer treatments including PTX-100 and novel cell therapies.

Phoslock Environmental Technologies reports a sharp revenue increase driven by Brazil and international markets, yet continues to face significant losses and ongoing legal challenges.